Global medical technology company MGC Diagnostics and Neurovirtual USA have entered into an agreement under which MGC Diagnostics will market and distribute the SleepVirtual BWII PSG and BWIII PSG diagnostic polysomnography systems in the US and Canada.
The SleepVirtual BWII PSG and SleepVirtual BWIII PSG diagnostic polysomnography systems are indicated for use in the diagnosis and treatment of sleep apnea and sleep-related breathing disorders.
Incorporating small and lightweight design, the SleepVirtual BWII diagnostic polysomnography system may be used as a stationary unit or a portable unit.
The SleepVirtual BWIII PSG Plus system is a larger device with combined sleep and neuro-diagnostics capabilities.
MGC Diagnostics global marketing, engineering and corporate strategy executive vice president Todd Austin noted that the exclusive distribution partnership with SleepVirtual is an example of how the company continues to execute strategic partnerships with best in class providers of technology serving adjacent cardiorespiratory diagnostic markets.
"Together with SleepVirtual, MGC Diagnostics is well positioned to provide diagnostic capabilities to physicians managing complex patients, including patients with both COPD (chronic obstructive pulmonary disease) and OSA (obstructive sleep apnea).
"Leveraging MGC Diagnostic’s global sales, marketing, and support network provides our customers best-in-class access to cardiorespiratory healthcare professionals and their patients throughout the world," Austin added.